News

The new 92-bed treatment facility will be jointly operated by the UK’s Department for International Development (DfID) and charity organisation, Save the Children. The centre includes an 80-bed

The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the

Multiple sclerosis is a chronic inflammatory demyelinating and neurodegenerative disease of the central nervous system. The EMPIRE trial is designed to evaluate the efficacy, safety, tolerability and pharmacokinetics

A total of 150 patients will be enrolled in the randomized, double-blind trial, which is designed to evaluate RUT58-60’s safety, tolerability and potential efficacy for use as an

SSc or scleroderma is a connective tissue disease of autoimmune origin with severe physical and psychosocial consequences. IVA337 is a patent protected new chemical entity (NCE) that has

Under the agreement, MDD has the rights to market, sell and distribute Imprimis’ patent-pending Go Dropless™ formulations and other ophthalmic formulations in Puerto Rico. In addition, the agreement

K-Ras is the most commonly mutated oncogene in human cancers, with about 30% of all cancers harbouring activating ras mutations. Furthermore, cancers with a high prevalence of K-Ras

THR-18 is novel drug-candidate designed to reduce or neutralize the life-threatening adverse effects of tPA. The study has successfully defined the maximal tolerated and safe dose of THR-18

The proposed trial will recruit 10 patients with metastatic breast cancer and will involve 4 monthly injections of the dCellVax gene-silenced dendritic cell therapy. The trial will last